Based on our inclusion strategy, 34 of the 57 studies (60%) reported any data on liver abnormalities.20, 21, 22 , 25 , 27 , 28 , 30 , 34, 35, 36 , 38 , 41, 42, 43 , 45 , 48, 49, 50, 51, 52, 53 , 55 , 57 , 60 , 61 , 63 , 65, 66, 67 , 70, 71, 72 , 75 , 76 The majority of the studies that reported data on LFTs only reported continuous summary statistics (median and interquartile range) without reporting the number of patients with abnormal levels. Abnormal aspartate transaminase (AST), defined as any value above the upper limit of normal (ULN), was reported in 15.0% (95% CI, 13.6%– 16.5) of patients across 16 studies, including 2514 COVID-19 patients. Abnormal alanine transaminase (ALT), defined as any value above the ULN, was reported in 15.0% (95% CI, 13.6%–16.4%) of patients across 17 studies including 2711 COVID-19 patients. Abnormal bilirubin, defined as any value above the ULN, was reported in 16.7% (95% CI, 15.0%–18.5%) of patients across 10 studies including 1841 COVID-19 patients. All patients had confirmed COVID-19 by laboratory RT-PCR testing.